Cancer Network Staff

A study found varying degrees of costs and benefits associated with granting early access to drugs based on PFS. In many cases, costs outstripped the benefits.

A retrospective analysis found that high expression levels of two angiogenic factors were associated with poor prognosis in esophageal cancer.

A single-arm, open-label trial in Australia found that selective early switching from imatinib to nilotinib is feasible and effective in patients with CML.

CML patients with high CIP2A levels treated with second-generation tyrosine kinase inhibitors have better outcomes than those treated with imatinib.

Expression of the IGF2BP1 gene was associated with more advanced tumors and decreased patient survival in neuroblastoma, suggesting its prognostic value.

Final results of the trial that led to FDA approval show that a new 9-valent HPV vaccine can reduce cases of HPV and cervical cancer.

A new study yielded nomograms for the assessment of locally advanced cervical cancer, with prognostic factors including histology, performance status, and others.

A retrospective analysis suggested that a declining proportion of patients with lung cancer would meet the criteria for undergoing low-dose CT screening.

In a phase II study, the use of maintenance sunitinib improved progression-free survival among patients with untreated extensive-stage small-cell lung cancer.

A classification system known as Lung-RADS reduced false positive rates but also decreased the sensitivity of low-dose CT screening compared with NLST standards.

Cervical cancer survivors saw improvements in self-reported quality-of-life outcomes with a psychosocial telephone counseling intervention, according to a new study.

In two phase II trials, the protein synthesis inhibitor omacetaxine offered long-term efficacy in some patients with chronic-phase and accelerated-phase CML.

Researchers have shown that axitinib could be repurposed as a treatment for CML patients resistant to standard TKIs through a certain molecular mechanism.

Women in routine gynecologic care expressed willingness to extend screening intervals and use cytology alone or Pap-HPV cotesting if recommended by a physician.

An inhibitor of osteoclast formation can stop the proliferation of dormant tumor cells that in some breast cancer survivors turn into bone metastases.

Conservative management of cervical intraepithelial neoplasia (CIN) grade 2 is an appropriate treatment option for women aged 25 years and younger.

Active surveillance is effective and yields good outcomes in patients with clinical stage I testicular cancer who underwent orchiectomy.

A test for dangerous strains of high-risk HPV using messenger RNA was shown to be reliable and effective for cervical cancer risk stratification.

A study of nivolumab compared with docetaxel in patients with squamous cell NSCLC was stopped early after an analysis showed superiority of the study drug.